株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

全ゲノム&エクソームシーケンシングの世界市場 (2019-2023年):研究・臨床・DTC・アグリバイオ・腫瘍細胞用途

Whole Genome and Exome Sequencing Markets by Research, Clinical, Direct to Consumer, AgriBio & Tumor including Test Price and Volume Forecasts with Executive and Consultant Guides 2020 to 2024

発行 Howe Sound Research 商品コード 567248
出版日 ページ情報 英文 417 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=109.71円で換算しております。
Back to Top
全ゲノム&エクソームシーケンシングの世界市場 (2019-2023年):研究・臨床・DTC・アグリバイオ・腫瘍細胞用途 Whole Genome and Exome Sequencing Markets by Research, Clinical, Direct to Consumer, AgriBio & Tumor including Test Price and Volume Forecasts with Executive and Consultant Guides 2020 to 2024
出版日: 2019年10月02日 ページ情報: 英文 417 Pages
概要

当レポートでは、世界の全ゲノムおよびエクソームシーケンシングの市場を調査し、市場および技術の概要、各種関連事業者・組織・機関とその役割、各種用途と導入事例、産業構造、主要企業、市場成長への各種影響因子の分析、企業および研究機関などの近年の取り組み、地域/主要国別の実施件数・価格・収益規模の推移と予測、将来の展望などをまとめています。

第1章 イントロダクション・市場の定義

第2章 市場概要

  • 関連事業者と役割
  • 用途・例・ディスカッション
    • DTC
    • 研究
    • 臨床
    • 病原体検査
    • アグリバイオ
  • 産業構造
  • 主要企業のプロファイル

第3章 市場動向

  • 市場成長促進因子
  • 市場成長抑制因子
  • シーケンシング装置

第4章 WGES (全ゲノム&エクソームシーケンシング):近年の展開

第5章 北米市場の分析・予測

  • 件数・価格・収益:用途・国別
    • 米国
    • カナダ
      • 研究
      • 臨床
      • アグリバイオ
      • DTC検査
      • 腫瘍細胞

第6章 欧州市場の分析・予測

  • 件数・価格・収益:用途・国別
    • フランス
    • ドイツ
    • 英国
    • スペイン
    • イタリア
    • ロシア
    • その他の欧州・旧ソ連
      • 研究
      • 臨床
      • アグリバイオ
      • DTC検査
      • 腫瘍細胞

第7章 アジア太平洋市場の分析・予測

  • 件数・価格・収益:用途・国別
    • 中国
    • 日本
    • 韓国
    • インド
    • オーストラリア
    • その他
      • 研究
      • 臨床
      • アグリバイオ
      • DTC検査
      • 腫瘍細胞

第8章 ラテンアメリカ・アフリカ・中東市場の分析・予測

  • 件数・価格・収益:用途・地域別
    • 研究
    • 臨床
    • アグリバイオ
    • DTC検査
    • 腫瘍細胞

第9章 世界市場の分析・予測:サマリー

  • 件数・価格・収益:用途別
    • 研究
    • 臨床
    • アグリバイオ
    • DTC検査
    • 腫瘍細胞

第10章 全ゲノムシーケンシング:将来のビジョン

付録

図表

Table of Tables

  • Table 1 The Base Pairs
  • Table 2 Most Common Traditional Genetic Disorders
  • Table 3 Medicare Clinical Lab Expenditures Actual & Forecast 2004 to 2020 ($Billion)
  • Table 4 List of GLOBAL SEQUENCING LOCATIONS
  • Table 5 Market Players by Type
  • Table 6 The Different Markets for Whole Genome Sequencing
  • Table 7 DTC Sub Segments
  • Table 8 Roles of WGS in AgriBio
  • Table 9 The Factors Driving Growth
  • Table 10 Factors Limiting Growth
  • Table 11 - Listing of Current NGS Instrument Specifications
  • Table 12 Six New Sequencing Technologies
  • Table 13 USA Research - Volume Price and Revenue Forecast
  • Table 14 USA Clinical - Volume Price and Revenue Forecast
  • Table 15 USA AgriBio - Volume Price and Revenue Forecast
  • Table 16 USA Direct to Consumer Testing - Volume Price and Revenue Forecast
  • Table 17 USA Tumor - Volume Price and Revenue Forecast
  • Table 18 Canada Research - Volume Price and Revenue Forecast
  • Table 19 Canada Clinical - Volume Price and Revenue Forecast
  • Table 20 Canada AgriBio - Volume Price and Revenue Forecast
  • Table 21 Canada Direct to Consumer Testing - Volume Price and Revenue Forecast
  • Table 22 Canada Tumor - Volume Price and Revenue Forecast
  • Table 23 France Research - Volume Price and Revenue Forecast
  • Table 24 France Clinical - Volume Price and Revenue Forecast
  • Table 25 France AgriBio - Volume Price and Revenue Forecast
  • Table 26 France Direct to Consumer Testing - Volume Price and Revenue Forecast
  • Table 27 France Tumor - Volume Price and Revenue Forecast
  • Table 28 Germany Research - Volume Price and Revenue Forecast
  • Table 29 Germany Clinical - Volume Price and Revenue Forecast
  • Table 30 Germany AgriBio - Volume Price and Revenue Forecast
  • Table 31 Germany Direct to Consumer Testing - Volume Price and Revenue Forecast
  • Table 32 Germany Tumor - Volume Price and Revenue Forecast
  • Table 33 U.K. Research - Volume Price and Revenue Forecast
  • Table 34 U.K. Clinical - Volume Price and Revenue Forecast
  • Table 35 U.K. AgriBio - Volume Price and Revenue Forecast
  • Table 36 U.K. Direct to Consumer Testing - Volume Price and Revenue Forecast
  • Table 37 U.K. Tumor - Volume Price and Revenue Forecast
  • Table 38 Spain Research - Volume Price and Revenue Forecast
  • Table 39 Spain Clinical - Volume Price and Revenue Forecast
  • Table 40 Spain AgriBio - Volume Price and Revenue Forecast
  • Table 41 Spain Direct to Consumer Testing - Volume Price and Revenue Forecast
  • Table 42 Spain Tumor - Volume Price and Revenue Forecast
  • Table 43 Italy Research - Volume Price and Revenue Forecast
  • Table 44 Italy Clinical - Volume Price and Revenue Forecast
  • Table 45 Italy AgriBio - Volume Price and Revenue Forecast
  • Table 46 Italy Direct to Consumer Testing - Volume Price and Revenue Forecast
  • Table 47 Italy Tumor - Volume Price and Revenue Forecast
  • Table 48 Russia Research - Volume Price and Revenue Forecast
  • Table 49 Russia Clinical - Volume Price and Revenue Forecast
  • Table 50 Russia AgriBio - Volume Price and Revenue Forecast
  • Table 51 Russia Direct to Consumer Testing - Volume Price and Revenue Forecast
  • Table 52 Russia Tumor - Volume Price and Revenue Forecast
  • Table 53 Rest of Europe Research - Volume Price and Revenue Forecast
  • Table 54 Rest of Europe Clinical - Volume Price and Revenue Forecast
  • Table 55 Rest of Europe AgriBio - Volume Price and Revenue Forecast
  • Table 56 Rest of Europe Direct to Consumer Testing - Volume Price and Revenue Forecast. 306
  • Table 57 Rest of Europe Tumor - Volume Price and Revenue Forecast
  • Table 58 China Research - Volume Price and Revenue Forecast
  • Table 59 China Clinical - Volume Price and Revenue Forecast
  • Table 60 China AgriBio - Volume Price and Revenue Forecast
  • Table 61 China Direct to Consumer Testing - Volume Price and Revenue Forecast
  • Table 62 China Tumor - Volume Price and Revenue Forecast
  • Table 63 Japan Research - Volume Price and Revenue Forecast
  • Table 64 Japan Clinical - Volume Price and Revenue Forecast
  • Table 65 Japan AgriBio - Volume Price and Revenue Forecast
  • Table 66 Japan Direct to Consumer Testing - Volume Price and Revenue Forecast
  • Table 67 Japan Tumor - Volume Price and Revenue Forecast
  • Table 68 South Korea Research - Volume Price and Revenue Forecast
  • Table 69 South Korea Clinical - Volume Price and Revenue Forecast
  • Table 70 South Korea AgriBio - Volume Price and Revenue Forecast
  • Table 71 South Korea Direct to Consumer Testing - Volume Price and Revenue Forecast
  • Table 72 South Korea Tumor - Volume Price and Revenue Forecast
  • Table 73 India Research - Volume Price and Revenue Forecast
  • Table 74 India Clinical - Volume Price and Revenue Forecast
  • Table 75 India AgriBio - Volume Price and Revenue Forecast
  • Table 76 India Direct to Consumer Testing - Volume Price and Revenue Forecast
  • Table 77 India Tumor - Volume Price and Revenue Forecast
  • Table 78 Australia Research - Volume Price and Revenue Forecast
  • Table 79 Australia Predictive Testing - Volume Price and Revenue Forecast
  • Table 80 Australia AgriBio - Volume Price and Revenue Forecast
  • Table 81 Australia Direct to Consumer Testing - Volume Price and Revenue Forecast
  • Table 82 Australia Tumor - Volume Price and Revenue Forecast
  • Table 83 Rest of Asia Pacific Research - Volume Price and Revenue Forecast
  • Table 84 Rest of Asia Pacific Clinical - Volume Price and Revenue Forecast
  • Table 85 Rest of Asia Pacific AgriBio- Volume Price and Revenue Forecast
  • Table 86 Rest of Asia Pacific Direct to Consumer Testing - Volume Price and Revenue Forecast
  • Table 87 Rest of Asia Pacific Tumor - Volume Price and Revenue Forecast
  • Table 88 Brazil Research - Volume Price and Revenue Forecast
  • Table 89 Brazil Clinical - Volume Price and Revenue Forecast
  • Table 90 Brazil AgriBio- Volume Price and Revenue Forecast
  • Table 91 Brazil Direct to Consumer Testing - Volume Price and Revenue Forecast
  • Table 92 Brazil Tumor - Volume Price and Revenue Forecast
  • Table 93 Mexico Research - Volume Price and Revenue Forecast
  • Table 94 Mexico Clinical - Volume Price and Revenue Forecast
  • Table 95 Mexico AgriBio - Volume Price and Revenue Forecast
  • Table 96 Mexico Direct to Consumer Testing - Volume Price and Revenue Forecast
  • Table 97 Mexico Tumor - Volume Price and Revenue Forecast
  • Table 98 Rest of Latin America Research - Volume Price and Revenue Forecast
  • Table 99 Rest of Latin America Clinical - Volume Price and Revenue Forecast
  • Table 100 Rest of Latin America AgriBio- Volume Price and Revenue Forecast
  • Table 101 Rest of Latin America Direct to Consumer Testing - Volume Price and Revenue Forecast
  • Table 102 Rest of Latin America Tumor - Volume Price and Revenue Forecast
  • Table 103 Africa & Middle East Research - Volume Price and Revenue Forecast
  • Table 104 Africa & Middle East Clinical - Volume Price and Revenue Forecast
  • Table 105 Africa & Middle East AgriBio- Volume Price and Revenue Forecast
  • Table 106 Africa & Middle East Direct to Consumer Testing - Volume Price and Revenue Forecast
  • Table 107 Africa & Middle East Tumor - Volume Price and Revenue Forecast
  • Table 108 Global Research - Volume Price and Revenue Forecast
  • Table 109 Global Clinical - Volume Price and Revenue Forecast
  • Table 110 Global AgriBio - Volume Price and Revenue Forecast
  • Table 111 Global Direct to Consumer Testing - Volume Price and Revenue Forecast
  • Table 112 Global Tumor - Volume Price and Revenue Forecast
  • Table 113 2019 Clinical Lab Fee Schedule

Table of Figures

  • Figure 1 Medicare Clinical Lab Expenditures 2004 to 2020 ($Million)
  • Figure 2 Size of Genome for Various Species
  • Figure 3 - Cost To Sequence a Human Genome
目次

Will all newborns receive Whole Genome Sequencing at birth? How fast will Direct to Consumer Testing grow? What sequencing technology will take the lead? What's holding the industry back? Where are the over 800 locations that have high throughput devices?

Our facts and support = Your success.

A plummeting of costs for Whole Genome Sequencing is creating a gold rush for market players. New consumers, new technologies, new specializations. In a situation reminiscent of the birth of the internet industry a wide range of well funded players are racing for market share on a truly global stage. The report forecasts the market size out to 2023. The report includes detailed breakouts for 14 countries and 5 regions.

Tumor Cell Sequencing? Direct to Consumer? Gene Expression? Find out about the technology in readily understood terms that explain the jargon. What are the issues? Find the opportunities, and the pitfalls. Understand growth expectations and the ultimate market forecasts for the next five years.

Our research makes you the expert in your organization. Get our research team working for you by ordering all, or a portion, of this comprehensive report. Your credit card order sends the report to your inbox instantly. Check all your licensing options but don't worry, your order is available as a credit if you wish to upgrade to more information. We wrote this report and we are ready, by phone or email, to help you use it. As always, assistance, and additional specific data, is provided without additional charges.

All report data is available in Excel format on request.

Make investment decisions and valuations with confidence using the latest data.

ABOUT THE LEAD AUTHOR

Mr. Greg Powell, B.SC., M.B.A is the President of Howe Sound Research. He is an experienced business and clinical professional. He is co-author of the paper "The Radioimmunoassay of Angiotensinogen by Antibody Trapping." He has worked in laboratory testing and management for over 20 years. Mr. Powell's education includes:

B.Sc. (Chemistry) University of BC

M.B.A. (Finance and Policy) University of BC

Market Research Seminar - Burke Institute

Finance for Senior Executives - Harvard Business School

Table of Contents

  • i. Whole Genome Sequencing Market - Strategic Situation Analysis
  • ii. Guide for Executives, Marketing, Sales and Business Development Staff
  • iii. Guide for Management Consultants and Investment Advisors

1. Introduction and Market Definition

  • 1.1 Whole Genome Sequencing Definition In This Report
    • 1.1.1 Whole and Exome Sequencing
    • 1.1.2 Research and Clinical
    • 1.1.3 Direct to Consumer
    • 1.1.4 AgriBio
    • 1.1.5 Tumor Cells
  • 1.2 The Genomics Revolution
  • 1.3 Market Definition
    • 1.3.1 Volumes
    • 1.3.2 Prices
    • 1.3.3 Revenue Market Size
  • 1.4 U.S. Medical Market and laboratory Testing - Perspective
    • 1.4.1 U.S. Medicare Expenditures for laboratory testing
  • 1.5 Sizing the Genome - Not What You Think
    • 1.5.1 Cost, Price and Genome Size, Pricing Practice

1A GLOBAL LISTING OF HIGH THROUGHPUT SEQUENCING ESTABLISHMENTS INSTALLED BASE - Location & Contacts

2. Market Overview

  • 2.1 Market Participants Play Different Roles
    • 2.1.1 Instrument Manufacturer
    • 2.1.2 Independent lab specialized/esoteric
    • 2.1.3 Independent lab national/regional
    • 2.1.4 Independent lab analytical
    • 2.1.5 Public National/regional lab
    • 2.1.6 Hospital lab
    • 2.1.7 Physician lab
    • 2.1.8 DTC Lab
    • 2.1.9 Sequencing Labs
    • 2.1.10 Audit body
  • 2.2 Whole Genome Sequencing -Markets, Examples and Discussion
    • 2.2.1 Direct to Consumer - Two Approaches
      • 2.2.1.1 The New Age of Medical Information
      • 2.2.1.2 Dangers in DTC-WGS - Health Costs and Regulation
      • 2.2.1.3 Newborn and Prenatal - A Brave New World
      • 2.2.1.4 DTC - How Many Segments?
    • 2.2.2 Research Markets
      • 2.2.2.1 Research Funding and Capital Expense
      • 2.2.2.2 WGS Datasets Preferred
      • 2.2.2.3 Existing research repurposed
      • 2.2.2.4 Organism Wide Market
      • 2.2.2.5 Service Suppliers Respond
    • 2.2.3 Clinical - Understanding Germline and Somatic
      • 2.2.3.1 Somatic - Chasing Mutations and Pharmacogenomics
    • 2.2.4 Pathogen Testing
      • 2.2.4.1 The Hepatitis C Story
      • 2.2.4.2 Will the Microbiology Department Disappear?
    • 2.2.5 AgriBio - Big Business
      • 2.2.5.1 GMO is Here to Stay
      • 2.2.5.2 WGS Benefits and Risks
      • 2.2.5.3 The New Agriculture
  • 2.3 Industry Structure
    • 2.3.1 Hospital's Testing Share
    • 2.3.2 Economies of Scale
    • 2.3.3 Instrument Manufacturer Role
    • 2.3.4 Healthcare Industry Impacts - Still Struggling
      • 2.3.4.1 Can the Healthcare Industry Adapt?
      • 2.3.4.2 Genetic Counselling as an Industry
      • 2.3.4.3 WGES Adoption and Cannibalization
      • 2.3.4.4 The Meaning of Grail
  • 2.4 Profiles of Key Companies
    • 10x Genomics, Inc
    • 23andME Inc
    • Agilent
    • Ancestry.com LLC
    • Baylor Miraca Genetics Laboratories
    • BGI Genomics Co. Ltd
    • Bio-Rad Laboratories, Inc.
    • Centogene
    • Color Genomics
    • Complete Genomics, Inc. - A BGI Company
    • Dante Labs
    • Datar Cancer Genetics Limited
    • Fabric Genomics
    • GE Global Research
    • Gencove
    • Gene by Gene, Ltd.
    • Genewiz
    • Genomic Health
    • Genomics England
    • Genomics Personalized Health (GPH)
    • Grail, Inc
    • Helix
    • Human Longevity, Inc.
    • Illumina
    • Invitae Corporation
    • Macrogen
    • Medgenome
    • MNG Labs
    • Nebula Genomics
    • Novogene Bioinformatics Technology Co., Ltd
    • Omega Bioservices
    • ORIG3N, Inc.
    • Oxford Nanopore Technologies
    • Pacific Biosciences
    • Perkin Elmer
    • Personalis
    • Qiagen Gmbh
    • Regeneron
    • Roche Molecular Diagnostics
    • Roswell Biotechnologies
    • Sequencing.com
    • Stratos Genomics
    • Sure Genomics, Inc.
    • Veritas Genetics

3. Market Trends

  • 3.1 Factors Driving Growth
    • 3.1.1 Diagnostic Factors
    • 3.1.2 Interpreting the Code Otherwise.
    • 3.1.3 Changes in Agriculture.
    • 3.1.4 Fertility Technology Comes of Age
    • 3.1.5 Pathogen Challenges
  • 3.2 Factors Limiting Growth
    • 3.2.1 Increased Competition Lowers Price
    • 3.2.2 Lower Costs
    • 3.2.3 Healthcare Cost Concerns Curtail Growth.
    • 3.2.4 Wellness has a downside
    • 3.2.5 GMO Opposition Movement.
  • 3.3 Sequencing Instrumentation
    • 3.3.1 Instrumentation Tenacity.
    • 3.3.2 Declining Cost of Instruments Changes Industry Structure.
    • 3.3.3 LISTING of CURRENT NGS INSTRUMENT SPECIFICATIONS.
    • 3.3.4 Oxford Nanopore
      • 3.3.4.1 What is Oxford Nanopore Sequencing?
      • 3.3.4.2 What can Oxford Nanopore Sequencingt be used for?
      • 3.3.4.3 Oxford Nanopore Products
    • 3.3.5 Long Reads - Further Segmentation
    • 3.3.6 Linked Reads
    • 3.3.7 Targeted Sequencing Adopts CRISPR
    • 3.3.8 New Sequencing Technologies

4. WGES Recent Developments

  • 4.1 Recent Developments - Importance and How to Use This Section
    • 4.1.1 Importance of These Developments
    • 4.1.2 How to Use This Section
      • UK Whole-Genome Sequencing Project Obtains £200M
      • WGS may help with disease outbreaks
      • VERITAS CUTS WGS PRICE BY 40%
      • Dante Labs Launches GenomeL, Long Reads Human Whole Genome Sequencing
      • Machine-learning system used to diagnose genetic diseases
      • Whole Genome Sequencing for healthy creates controversy
      • 100,000 whole genomes sequenced in the NHS
      • Nebula Genomics Offers FREE Whole Genome Sequencing
      • Veritas Genetics has time limited WGS offer for $199
      • Veritas Genetics Launches Two New Whole Genome Sequencing Products
      • BGI unveils a powerful new sequencer
      • State of California Funds $2M Whole-Genome Sequencing Pilot
      • Rapid genome sequencing could revolutionize health care
      • Human Longevity Launches Whole Genome Product, MassMutual Partnerships
      • $1500 to sequence newborns in China
      • Konica Minolta to buy Ambry Genetics, deal worth up to $1 billion
      • PerkinElmer Launches Clinical Whole Genome Sequencing Services
      • Veritas Genetics Buys Curoverse
      • Nine Centres use Oxford Nanopore MinION to Sequence Human Genome
      • Esperite and BGI Genomics sign a strategic agreement to offer Whole Genome Sequencing on a large scale
      • Easily Affordable Whole-genome Sequencing is Goal of Mayo Collaboration with Veritas
      • Regeneron Partners With AbbVie, Alnylam, AstraZeneca, Biogen, Pfizer to Sequence UK Biobank Samples
      • MedGenome Expands Its NGS Capabilities and Forays Into Single-Cell Sequencing
      • Genomics England Adopts Edico's Dragen For NGS Analysis
      • BGI Says It Will Slash Cost of Gene Testing to $300
      • Position Statement Spells Out Fetal Diagnostic Sequencing Recommendations
      • Inova, Veritas Genetics Partner to Offer Whole-Genome Sequencing, Interpretation
      • Dante Labs Announces 10,000 European Genome Project
      • PerkinElmer Extends Clinical Whole Genome Sequencing Services
      • Personalis Signs New Genome Sequencing Services Contract With VA
      • NorthShore Enlists Ambry Genetics for Whole-Exome Sequencing

5. Country Market Sizes - North America

  • 5.1 United States of America
    • 5.1.1 Research - Volumes, Prices, Revenues
    • 5.1.2 Clinical - Volumes, Prices, Revenues
    • 5.1.3 AgriBio - Volumes, Prices, Revenues
    • 5.1.4 Direct to Consumer Testing - Volumes, Prices, Revenues
    • 5.1.5 Tumor - Volumes, Prices, Revenues
  • 5.2 Canada
    • 5.2.1 Research - Volumes, Prices, Revenues
    • 5.2.2 Clinical - Volumes, Prices, Revenues
    • 5.2.3 AgriBio - Volumes, Prices, Revenues
    • 5.2.4 Direct to Consumer Testing - Volumes, Prices, Revenues
    • 5.2.5 Tumor - Volumes, Prices, Revenues

6. Country Markets - Europe

  • 6.1 France
    • 6.1.1 Research - Volumes, Prices, Revenues
    • 6.1.2 Clinical - Volumes, Prices, Revenues
    • 6.1.3 AgriBio - Volumes, Prices, Revenues
    • 6.1.4 Direct to Consumer Testing - Volumes, Prices, Revenues
    • 6.1.5 Tumor - Volumes, Prices, Revenues
  • 6.2 Germany
    • 6.2.1 Research - Volumes, Prices, Revenues
    • 6.2.2 Clinical - Volumes, Prices, Revenues
    • 6.2.3 AgriBio - Volumes, Prices, Revenues
    • 6.2.4 Direct to Consumer Testing - Volumes, Prices, Revenues
    • 6.2.5 Tumor - Volumes, Prices, Revenues
  • 6.3 United Kingdom
    • 6.3.1 Research - Volumes, Prices, Revenues
    • 6.3.2 Clinical - Volumes, Prices, Revenues
    • 6.3.3 AgriBio - Volumes, Prices, Revenues
    • 6.3.4 Direct to Consumer Testing - Volumes, Prices, Revenues
    • 6.3.5 Tumor- Volumes, Prices, Revenues
  • 6.4 Spain
    • 6.4.1 Research - Volumes, Prices, Revenues
    • 6.4.2 Clinical - Volumes, Prices, Revenues
    • 6.4.3 AgriBio - Volumes, Prices, Revenues
    • 6.4.4 Direct to Consumer Testing - Volumes, Prices, Revenues
    • 6.4.5 Tumor - Volumes, Prices, Revenues
  • 6.5 Italy
    • 6.5.1 Research - Volumes, Prices, Revenues
    • 6.5.2 Clinical - Volumes, Prices, Revenues
    • 6.5.3 AgriBio - Volumes, Prices, Revenues
    • 6.5.4 Direct to Consumer Testing - Volumes, Prices, Revenues
    • 6.5.5 Tumor - Volumes, Prices, Revenues
  • 6.6 Russia
    • 6.6.1 Research - Volumes, Prices, Revenues
    • 6.6.2 Clinical - Volumes, Prices, Revenues
    • 6.6.3 AgriBio Testing - Volumes, Prices, Revenues
    • 6.6.4 Direct to Consumer Testing - Volumes, Prices, Revenues
    • 6.6.5 Tumor - Volumes, Prices, Revenues
  • 6.7 Remainder of Europe and Former Soviet Union
    • 6.7.1 Research - Volumes, Prices, Revenues
    • 6.7.2 Clinical - Volumes, Prices, Revenues
    • 6.7.3 AgriBio - Volumes, Prices, Revenues
    • 6.7.4 Direct to Consumer Testing - Volumes, Prices, Revenues
    • 6.7.5 Tumor - Volumes, Prices, Revenues

7. Country Markets - Asia Pacific

  • 7.1 China
    • 7.1.1 Research - Volumes, Prices, Revenues
    • 7.1.2 Clinical - Volumes, Prices, Revenues
    • 7.1.3 AgriBio - Volumes, Prices, Revenues
    • 7.1.4 Direct to Consumer Testing - Volumes, Prices, Revenues
    • 7.1.5 Tumor - Volumes, Prices, Revenues
  • 7.2 Japan
    • 7.2.1 Research - Volumes, Prices, Revenues
    • 7.2.2 Clinical - Volumes, Prices, Revenues
    • 7.2.3 AgriBio - Volumes, Prices, Revenues
    • 7.2.4 Direct to Consumer Testing - Volumes, Prices, Revenues
    • 7.2.5 Tumor - Volumes, Prices, Revenues
  • 7.3 South Korea
    • 7.3.1 Research - Volumes, Prices, Revenues
    • 7.3.2 Clinical - Volumes, Prices, Revenues
    • 7.3.3 AgriBio - Volumes, Prices, Revenues
    • 7.3.4 Direct to Consumer Testing - Volumes, Prices, Revenues
    • 7.3.5 Tumor - Volumes, Prices, Revenues
  • 7.4 India
    • 7.4.1 Research - Volumes, Prices, Revenues
    • 7.4.2 Clinical - Volumes, Prices, Revenues
    • 7.4.3 AgriBio - Volumes, Prices, Revenues
    • 7.4.4 Direct to Consumer Testing - Volumes, Prices, Revenues
    • 7.4.5 Tumor - Volumes, Prices, Revenues
  • 7.5 Australia
    • 7.5.1 Research - Volumes, Prices, Revenues
    • 7.5.2 Clinical - Volumes, Prices, Revenues
    • 7.5.3 AgriBio - Volumes, Prices, Revenues
    • 7.5.4 Direct to Consumer Testing - Volumes, Prices, Revenues
    • 7.5.5 Tumor - Volumes, Prices, Revenues
  • 7.6 Rest of Asia Pacific
    • 7.6.1 Research - Volumes, Prices, Revenues
    • 7.6.2 Clinical - Volumes, Prices, Revenues
    • 7.6.3 AgriBio- Volumes, Prices, Revenues
    • 7.6.4 Direct to Consumer Testing - Volumes, Prices, Revenues
    • 7.6.5 Tumor - Volumes, Prices, Revenues

8. Country Markets - Latin America, Africa & The Middle East

  • 8.1 Brazil
    • 8.1.1 Research - Volumes, Prices, Revenues
    • 8.1.2 Clinical - Volumes, Prices, Revenues
    • 8.1.3 AgriBio- Volumes, Prices, Revenues
    • 8.1.4 Direct to Consumer Testing - Volumes, Prices, Revenues
    • 8.1.5 Tumor - Volumes, Prices, Revenues
  • 8.2 Mexico
    • 8.2.1 Research - Volumes, Prices, Revenues
    • 8.2.2 Clinical - Volumes, Prices, Revenues
    • 8.2.3 AgriBio - Volumes, Prices, Revenues
    • 8.2.4 Direct to Consumer Testing - Volumes, Prices, Revenues
    • 8.2.5 Tumor - Volumes, Prices, Revenues
  • 8.3 Rest of Latin America
    • 8.3.1 Research - Volumes, Prices, Revenues
    • 8.3.2 Clinical - Volumes, Prices, Revenues
    • 8.3.3 AgriBio - Volumes, Prices, Revenues
    • 8.3.4 Direct to Consumer Testing - Volumes, Prices, Revenues
    • 8.3.5 Tumor - Volumes, Prices, Revenues
  • 8.4 Africa & The Middle East
    • 8.4.1 Research - Volumes, Prices, Revenues
    • 8.4.2 Clinical - Volumes, Prices, Revenues
    • 8.4.3 AgriBio- Volumes, Prices, Revenues
    • 8.4.4 Direct to Consumer Testing - Volumes, Prices, Revenues
    • 8.4.5 Tumor - Volumes, Prices, Revenues

9. Global Market Summary

  • 9.1 Global Market
    • 9.1.1 Research - Volumes, Prices, Revenues
    • 9.1.2 Clinical - Volumes, Prices, Revenues
    • 9.1.3 AgriBio - Volumes, Prices, Revenues
    • 9.1.4 Direct to Consumer Testing - Volumes, Prices, Revenues
    • 9.1.5 Tumor - Volumes, Prices, Revenues

10. Vision of the Future of Whole Genome Sequencing

Appendices

  • I. United States Medicare System: January 2019 laboratory Fees Schedule
  • II Methodology
    • II.1 Authors
    • II.2 Sources
Back to Top